Clinical Trials, Research, and FDA Actions

摘要

According to a study published in the August 19 issue of the New England Journal of Medicine, Bristol-Myers Squibb's ipili-mumab was found to improve overall survival in patients with metastatic melanoma. The phase 3 trial of the targeted T-cell antibody was conducted with 676 patients who had previously received treatment for their disease. Patients given ipilimumab in addition to a peptide vaccine had a median survival of 10 months, compared with 6.4 months for patients who received the ipilimumab vaccine alone (P<.001), as well as a near doubling of survival rates at 12 months (46 percent vs. 25 percent) and 24 months (24 percent vs. 14 percent).